According to a report by Reuters, Stripe and private equity firm Advent International are joining forces to acquire the digital payments company at a price of $60.50 apiece, or at a 27.7 percent premium potential over its $47.37 closing price prior to the report.

Stripe and Advent will take equal ownership if the transaction proceeds.

Photo from Pixabay

Declining Value

The acquisition buzz came after the notable decline in value of PayPal Holdings Inc. (NASDAQ:PYPL) amid the intensifying competition in the digital payments industry, once one of the biggest fintech winners in the world.

Shares have fallen by 23.9 percent over the past 12 months and are now down by more than 81 percent over the past five years.

CEO Enrique Lores has been leading a restructuring effort that includes dividing the company into three business units and targeting as much as $1.5 billion in cost savings over the next several years.

Block Inc. to Join

A report by CNBC, citing people familiar with the matter, said that Block Inc. is also considering joining Stripe and Advent in the acquisition, potentially funneling in $17 billion in investment.

Macquarie said that Block’s entry could provide additional benefits through its artificial intelligence and software capabilities and banking expertise through Cash App.

Analyst Maintains Neutral Stance

Following the report, investment firm Macquarie reiterated its neutral stance on PayPal Holdings Inc. (NASDAQ:PYPL), alongside a price target of $50.

It said that Advent and Stripe’s partnership could result in a private equity playbook focusing on cost discipline, organizational simplification, and operational improvement.

Reports from CNBC also said, citing people familiar with the matter, that Block Inc. could join Stripe and Advent in the partnership.

Lesser Hedge Fund Participation

While takeover speculation has dramatically improved investor sentiment, institutional conviction had been softening before the reports emerged.

Based on data from Insider Monkey, 76 hedge funds held stakes in PayPal as of the first quarter of the year, lower than the 78 hedge funds in the fourth quarter of 2025.

Collectively, the funds held $1.2 billion in their stake, significantly lower than the $2.087 billion quarter-on-quarter.

The rally came after Lucid Group, Inc. (NASDAQ:LCID) CEO Silvio Napoli forcefully debunked an exclusive news report by electric-vehicles.com, which cited two people privy to the matter as saying that restructuring adviser AlixPartners is set to deliver findings to the EV-maker’s board before its next meeting.

According to the EV-focused website, the strategic options under review include taking the Saudi-backed EV maker private or filing for Chapter 11 bankruptcy protection.

For illustration purposes only. Photo from Lucid Group

‘False Reports’

In a LinkedIn post, Napoli said that the company generally does not comment on rumors. However, the claims were far from the facts “that they require a direct response.”

“Lucid is not considering bankruptcy or a transaction to take the company private. Those reports are false. The Board did not explore either scenario. Period,” he firmly said.

“My priority is clear: turn this company around. That is where the leadership team and I are focused,” he added.

Investors are expected to get a clearer picture of the company’s financial health when it reports its earnings performance in the second quarter of the year on August 4. A conference call will be held after market close on the said date to elaborate on the results.

Sufficient Cash

Seeking to reassure investors after the sharp sell-off brought about by the report, Napoli said that Lucid Group, Inc. (NASDAQ:LCID) currently has “sufficient liquidity” to fund its operations well into next year.

Hedge Fund Participation Down

Institutional sentiment, however, notably weakened in the previous quarter of the year.

Based on data from Insider Monkey, 23 hedge funds held stakes in Lucid Group, Inc. (NASDAQ:LCID) in the first quarter of the year, markedly fewer than the 27 funds in the quarter prior.

Collectively, the funds held $59.9 million worth of stake, also a marked drop from the $66.86 million quarter-on-quarter.

While management’s denial immediately eased concerns about the company’s financial health, investors are likely to remain focused on Lucid Group, Inc.’s (NASDAQ:LCID) ability to improve vehicle demand and strengthen its financial position over the coming quarters.

Its earnings in the second quarter are expected to serve as the next major catalyst in determining whether Wednesday’s rally marks the start of a broader recovery or merely a short-lived relief bounce.

In an earnings call on Tuesday, the company said that it was optimistic about growing its revenues by 160 percent to 200 percent to a range of $130 million to $150 million, versus the $50 million last year.

For illustration purposes only. Photo from Pixabay/Pexels

The guidance was supported by an effective backlog of $100 million, providing investors with greater visibility into future revenues.

FY26 Still in the Red

The aggressive outlook helped investors look beyond the company’s weak earnings performance in the full fiscal year 2026, betting that its backlog and increasing AI exposure could mark the beginning of a new growth cycle.

Aehr Test Systems (NASDAQ:AEHR) said that its net loss went 82 percent deeper during the period, ending at $7.1 million versus the $3.9 million last year.

Revenues were also lower by 15 percent at $50 million versus $59 million year-on-year.

Q4 Swings to Profits

However, the company swung to a net profit of $1.4 million in the fourth quarter of fiscal year 2026 from a net loss of $2.9 million in the same period last year, as revenues surged by 33 percent to $18.8 million from $14.1 million year-on-year.

Bookings finished at a record of $60.7 million, while backlogs ended at $80.6 million.

Effective backlog, including bookings since May 29, was at $100.6 million.

Aehr Test Systems (NASDAQ:AEHR) President and CEO Gayn Erickson said that they were pleased with the results, “which exceeded expectations and capped a year of significant bookings and revenue diversification for Aehr.”

“[Our] record quarterly bookings, a very strong backlog, and growing demand across AI processors, silicon photonics, and power semiconductors for our wafer-level and package-level burn-in solutions position us well for significant growth moving forward,” he said.

More Hedge Funds Buy In

More institutional investors are buying into shares of Aehr Test Systems (NASDAQ:AEHR).

Based on Insider Monkey’s database, 25 hedge funds held positions in the company as of the end of the first quarter of the year, up from 17 in the quarter prior.

Collectively, those funds own approximately $60.9 million worth of stake in the company, signaling that professional investors have been increasing their exposure ahead of what management expects to be a significant recovery.

[im-yf-promo]

While we acknowledge the potential of AEHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

MAHATHIR MOHD YASIN / Shutterstock.com,

The Coca-Cola Company, a beverage company, manufactures and sells various nonalcoholic beverages in the United States and internationally. KO continues to demonstrate the characteristics of a resilient, low-risk consumer staples business supported by strong earnings execution, steady volume growth, and improving investor sentiment.

Read More: 15 AI Stocks That Are Quietly Making Investors Rich

Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential

The company delivered a robust first quarter of 2026, reporting earnings per share of $0.86, comfortably ahead of the $0.81 consensus estimate, while organic revenue increased 10% and global unit case volume grew 3%, reflecting healthy demand across its portfolio despite a challenging consumer environment.

A key growth driver remained Coca-Cola Zero Sugar, which recorded 13% global growth, highlighting the success of the company’s innovation strategy and its ability to capture shifting consumer preferences toward lower-sugar beverages. Following the strong quarterly performance, Wall Street sentiment turned increasingly constructive, with Barclays, Wells Fargo, Citigroup, and Argus all raising their price targets to a range of $89–91, representing meaningful upside from the stock’s trading price of approximately $81.48.

Technically, Coca-Cola is consolidating just below its 52-week high of $82.66, positioning the shares for a potential breakout if positive business momentum continues. Management confidence is further reinforced by CEO James Quincey retaining 44,678 shares through an equity grant, aligning leadership with long-term shareholder interests. In addition, the company’s June 15 ex-dividend date, accompanied by a quarterly dividend of $0.53 per share, provides an additional near-term catalyst for income-focused investors.

The bullish thesis rests on continued strength in Coca-Cola Zero Sugar, sustained earnings momentum, and confirmation of these trends in the second quarter, which could support the stock reaching the $90–91 target range. While packaging cost inflation and softer consumer spending remain risks, Coca-Cola’s strong brand portfolio, pricing power, and consistent execution position the company favorably for continued shareholder returns.

Previously, we covered a bullish thesis on The Coca-Cola Company (KO) by Rijnberk InvestInsights in February 2025, which highlighted the company’s resilient earnings growth, pricing power, and dependable dividend despite macroeconomic headwinds. KO’s stock price has appreciated by approximately 20.63% since our coverage. Cameron Fen shares a similar view but emphasizes stronger earnings momentum, Coca-Cola Zero Sugar’s growth, analyst upgrades, and upside toward the $90–91 target range.

The Coca-Cola Company is not on our list of the 40 Most Popular Stocks Among Hedge Funds. Insider Monkey’s proprietary hedge fund data shows hedge fund sentiment is cooling. Institutional ownership dropped from 87 portfolios to 76 portfolios by the end of the first quarter. To evaluate KO’s potential, we consulted our Research Director, Dr. Inan Dogan, on whether the stock is a buy today.

Expert Analysis: Dr. Inan Dogan

“While I acknowledge the relatively strong performance of KO over the last 18 months, I don’t think it is the kind of stock you buy to outperform the market. KO returned an average of 9.5% annually over the last 10 years, which is a great return for a conservative investor looking to outperform the 4% to 5% returns generated by Treasury bonds. However, I believe investors can generate market-beating returns of 15% or more annually by investing in certain AI stocks. If you are looking for an AI stock that is more promising than KO and has 10,000% upside potential, check out my report on the cheapest AI stock.

Disclosure: No positions in KO.

]]> https://www.insidermonkey.com/blog/rbc-capital-reaffirms-outperform-rating-for-verastem-vstm-1802130/ Wed, 15 Jul 2026 15:43:12 +0000 https://www.insidermonkey.com/blog/?p=1802130 Verastem Inc. (NASDAQ:VSTM) is one of the 10 best stocks under $10 that could triple.

On July 7, RBC Capital maintained its Outperform rating on Verastem Inc. (NASDAQ:VSTM). The firm reduced the target price from $15 to $14, which still offers a revised upside potential of over 211%. The price target adjustment accompanies the firm’s broader biotech sector earnings preview for the second quarter.

RBC Capital highlighted the sector’s notable momentum during June, including a 2-week rally outpacing the S&P. This was supported by encouraging data around innovations, as well as a favorable sentiment regarding the FDA’s flexible stance.

The firm expects capital inflows to persist as the sector’s outlook offers more visibility compared to others. It acknowledged strong second quarter earnings across the sector, with more opportunities to achieve earnings beats, and maintains that the ongoing M&A activity is likely to offer more support.

Back on June 23, Verastem Inc. (NASDAQ:VSTM) revealed encouraging preliminary results from the company’s Phase 1/2 trial for the TARGET-D 101 study of VS-7375. It is an investigational oral inhibitor that targets KRAS G12D in patients with late-stage KRAS G12D-mutated tumors.

Results indicated promising clinical activity with a sound tolerability and safety profile across several tumor types and dosage levels. The tumors include advanced non-small cell lung cancer, metastatic colorectal cancer, and metastatic pancreatic ductal carcinoma.

Verastem Inc. (NASDAQ:VSTM) is a development-stage biopharmaceutical company involved in developing and commercializing drugs for the treatment of cancer. Its product candidates are Avutometinib, FAKZYNJA, Defactinib, VS-7375, CO-PACK, and AVMAPKI. The company is involved in clinical studies of RAMP 301, RAMP 205, FRAME, VS-7375-101, RAMP 203, and RAMP 201.

While we acknowledge the risk and potential of VSTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VSTM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On July 6, Lloyd Byrne from Jefferies reduced Sable Offshore Corp.’s (NYSE:SOC) price target from $24 to $11. Despite such a huge downward adjustment, the price target still results in an upside potential of over 180%.

Pixabay/Public Domain

The analyst maintained a Buy rating on the stock despite some recent challenges, such as the dilution for current equity holders caused by the recent convertible notes offering. The offering was executed amid the company’s failure to attain government support.

Earlier on July 1, Sable Offshore Corp. (NYSE:SOC) shared details around the company’s recent public offerings. These involved 32,467,533 common shares, priced at $3.08 per share, and the issuance of 6.5% convertible senior notes with a $300 million principal amount due in 2031.

The company offered underwriters a one-month period to purchase up to an additional 4,870,129 common shares and up to $45 million in additional notes, with the aim of covering excess allotments. The notes will fall under senior unsecured liabilities, accruing interest at 6.5% per year, that will be payable on a semi-annual basis.

The starting conversion rate is 249.7502 shares per $1,000 face value, with an estimated conversion price of $4 per share. This leads to a premium of about 30% over the public offering rate.

Sable Offshore Corp. (NYSE:SOC) is an oil and gas production company that conducts independent exploration, production, and marketing. In addition, the company operates a subsea pipeline that transports oil, gas, and produced water to the processing plants.

While we acknowledge the risk and potential of SOC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SOC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 29, Larimar Therapeutics Inc. (NASDAQ:LRMR) filed the first module of its Biologics License Application (BLA) to the U.S. FDA to get its Nomlabofusp therapy approved on an accelerated basis.  The company also plans to submit the other modules during the second half of 2026.

Tonhom1009/Shutterstock.com

In addition, Larimar revealed that the Nomlabofusp therapy had exhibited positive outcomes in an open-label study involving adult patients receiving daily injections to treat Friedreich’s ataxia.

According to the President and CEO, Carole Ben-Maimon, the new data is an important step in the development of the latest treatment method. It had been confirmed by the FDA that the existing data is enough to approve the application since it is based on skin frataxin, which is a new surrogate endpoint.

Later, on June 30, Christopher Chen from Baird reduced his target price for the stock from $7 to $5, which still offers more than 53% upside potential at the prevailing level. The analyst reiterated his Outperform rating on the stock, based on revisions to the firm’s model.

These revisions came at the back of the company’s Nomlabofusp therapy updates, indicating clinical benefits yet carrying certain safety concerns.

Larimar Therapeutics Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company that focuses on finding cures for rare illnesses through its innovative cell-penetrating peptide technology platform. Its primary candidate is CTI-1601, which is currently undergoing Phase 2 OLE trials in order to reach a cure for Friedreich’s ataxia.

While we acknowledge the risk and potential of LRMR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LRMR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On July 7, SAB Biotherapeutics Inc. (NASDAQ:SABS) and Breakthrough T1D, a leading research and advocacy firm for type 1 diabetes, disclosed that Breakthrough T1D has awarded a research grant to Michael J. Haller, M.D., Chief Pediatric Endocrinologist and Professor at the University of Florida. This grant has been given to support the PRISE-hATG, which is a clinical assessment of SAB-142 in Stage 3 T1D patients, who are somewhere between 100 days and 2 years away from disease diagnosis.

Copyright: dolgachov / 123RF Stock Photo

This study aims to evaluate whether SAB-142 has the capability to preserve endogenous C-peptide and regulate immune responses. It applies to individuals who carry residual beta cell activity after the initial 100 days following the diagnosis of Stage 3.

Back on June 24, Eliana Merle from Barclays initiated coverage of the stock with an Overweight rating. She set a target price of $13, which translates into an upside potential of more than 240% at the current level.

Merle noted that SAB-142 carries a lucrative opportunity as a disease-altering cure for type 1 diabetes. Going forward, she is anticipating the immunotherapy’s Phase 2b data to be a key catalyst for the stock, with results expected sometime during the second half of 2027.

SAB Biotherapeutics Inc. (NASDAQ:SABS) is a clinical-stage biopharmaceutical company that focuses on the development of human polyclonal immunotherapeutic antibodies. Its main product candidate is SAB-142 for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.

While we acknowledge the risk and potential of SABS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SABS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 25, AtaiBeckley N.V. (NASDAQ:ATAI) shared that the company will be included in the Russell indices following their latest reconstitution. The stock will become a part of the small-cap focused Russell 2000 Index, as well as the broader Russell 3000 Index, effective from June 29 onwards.

Likoper/Shutterstock.com

The company highlighted this as a significant development since more than $12 trillion worth of assets are benchmarked relative to the Russell indexes. The Russell 2000 Index tracks around 2,000 small-cap stocks, while the Russell 3000 Index covers around 3,000 small-, mid-, and large-cap stocks.

Later on July 7, Canaccord Genuity increased the price target on AtaiBeckley N.V. (NASDAQ:ATAI) from $15 to $17, resulting in an adjusted upside potential of over 227%. The firm also reiterated its Buy rating on the stock.

The price target revision came after the company revealed that it has concluded dosing for the final patient in relation to its Phase 2 Elumina trial of VLS-01 for treatment-resistant depression. The company is targeting Phase 3 development for major depressive disorder, with a possibility of expanding into generalized anxiety disorder.

AtaiBeckley N.V. (NASDAQ:ATAI) is a clinical-stage biopharmaceutical company involved in the research, development, and commercialization of mental health therapies. The company’s product pipeline consists of BPL-003 undergoing Phase 2 trials for treatment-resistant depression and alcohol addiction, as well as RL-007 being developed for cognitive decline from schizophrenia.

While we acknowledge the risk and potential of ATAI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATAI and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 15, Lexeo Therapeutics Inc. (NASDAQ:LXEO) disclosed that it has finalized the critical trial protocol of SUNRISE-FA 2. The company also finalized the statistical analysis plan meant to offer clinical evidence for submission of a Biologics License Application to the U.S. FDA.

Pressmaster/Shutterstock.com

The company highlighted that this submission is for the gene-based therapy candidate, LX2006, under the 2028 approval pathway. Lexeo’s Chief Medical Officer, Narinder Bhalla, M.D., labeled it as a major stride that involves the completion of a critical study design for SUNRISE-FA 2. He believes that it sets a path to assess LX2006 in Friedreich’s ataxia cardiomyopathy. He further stated:

“Patients living with FA, particularly those with cardiac involvement, have a significant unmet need for new treatment options and remain at the center of our efforts. This progress brings us one step closer to delivering a potential new therapy, and we remain focused on execution as we work to initiate the pivotal study and enroll the first patient by the end of the month.”

Later on June 25, JPMorgan reduced its target price for the stock from $12 to $9, which still yields an adjusted upside potential of over 92%. The firm reiterated an Overweight rating on the stock, based on a revised model that incorporates the company’s latest updates.

Lexeo Therapeutics Inc. (NASDAQ:LXEO) is a clinical-stage company that develops genetic medicines to treat genetic disorders. It is developing medicines which include an AAVrh10-based therapy known as LX2006, used for treating Friedreich’s ataxia associated with cardiomyopathy, and LX2020, which is developed to cure the heart muscles through gene delivery.

While we acknowledge the risk and potential of LXEO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LXEO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 30, Sharplink Inc. (NASDAQ:SBET) disclosed that it had purchased 10,000 Ether at an average price of $1,611 per ETH. This lifts its cumulative holdings to 886,725 tokens. The company also executed an open market buyback of more than 2.13 million of its common shares at an average rate of $4.69 per share, under its current stock repurchase program.

The company’s Chief Executive Officer, Joseph Chalom, reflected on Sharplink’s recently concluded $75 million registered direct offering, which he believes has improved the company’s financial standing and facilitated its dynamic strategy for ETH treasury management. He further stated:

“Our capital allocation philosophy is disciplined and straightforward: every financing decision we make is based on our long-term objective to increase ETH per share.”

Earlier on June 22, SharpLink Inc. (NASDAQ:SBET) revealed that it had signed an SPA with an institutional investor for the sale and purchase of more than 10 million of its common shares. The agreement also included attached warrants to buy common stock up to the designated amount. The underlying combined price was $7.49 per share and warrant, representing a 41% premium over the prevailing market price.

Sharplink Inc. (NASDAQ:SBET) focuses on the digital asset treasury business and operates as an institutional-grade Ethereum treasury platform. The company offers performance-based customer acquisition services for sportsbook and online casino gaming operators. It also drives user traffic and player acquisition for licensed gaming operators through PAS.net and a portfolio of U.S. state-specific digital properties.

While we acknowledge the risk and potential of SBET as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SBET and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 26, Omeros Corp. (NASDAQ:OMER) released an update regarding the Committee for Medicinal Products for Human Use’s (CHMP) review of a marketing authorization application for the company’s narsoplimab.  This antibody targets MASP-2 to cure hematopoietic stem cell transplant-related thrombotic microangiopathy.

oatautta/Shutterstock.com

After an oral explanation meeting, Omeros stated that the CHMP adopted a negative opinion on the filing. The company plans to request a reconsideration of the opinion and seek assessment by an Ad Hoc Expert Panel, which is an independent group of external clinical and scientific specialists to be assembled by the EMA.

Later, on June 26, Brandon Folkes from H.C. Wainwright cut the price target on Omeros Corp. (NASDAQ:OMER) from $40 to $33, which still implies an adjusted upside of more than 233%. The analyst kept a Buy rating on the stock despite an unfavorable opinion on Yartemlea shared by the CHMP.

Folkes labeled this development as a short-term headwind but does not consider this to be a major hurdle for the stock’s long-term potential. Further, he pointed to the antibody’s U.S. launch as the key value driver. He highlighted that the reduced price target incorporates increased forward-looking outlays on R&D and the removal of the EU opportunity from its valuation model.

Omeros Corp. (NASDAQ:OMER) is a clinical-stage biopharmaceutical developer that specializes in the discovery and development of drugs for immunologic diseases and rare diseases. The company’s drug candidate, Narsoplimab, is intended for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy.

While we acknowledge the risk and potential of OMER as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OMER and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On July 8, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) disclosed a CEO transition, and effective July 6, the company’s Co-founder and Chief Executive Officer, Richard Lowenthal, will no longer be employed by the company. Donn Casale, the company’s current President, has been appointed as the new CEO and Director, who will take charge from July 7 onwards.

anyaivanova/Shutterstock.com

The company shared that Casale has over 25 years of experience, covering the biopharma segment and commercial leadership roles. He has prior experience working as the Chief Commercial Officer with Dynavax Technologies, where he played a pivotal role in scaling up the annual revenues for hepatitis B cure, HEPLISAV-B(R), to more than $300 million. He helped the vaccine achieve more than 50% market share across the U.S. market prior to the acquisition of the company by Sanofi for $2.2 billion.

Back on June 24, ARS Pharmaceuticals Inc. (NASDAQ:SPRY) shared an update on the payer access for neffy, which is an epinephrine nasal spray. Based on the latest feedback, no new coverage decisions or commercial formulary inclusions have been released for neffy during the July 1 cycle.

ARS Pharma plans to continue collaborating with the rest of the payers and stated that neffy remains widely available to commercially insured individuals via direct coverage and a recently added retail cash option.

ARS Pharmaceuticals Inc. (NASDAQ:SPRY) is a biopharmaceutical company that is creating and selling medications meant for serious allergic reactions. The company has developed a product, neffy, which allows for the administration of epinephrine attacks without using needles to treat allergic reactions such as anaphylaxis.

While we acknowledge the risk and potential of SPRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SPRY and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

On June 29, Sagimet Biosciences Inc. (NASDAQ:SGMT) announced that it had been included in the broader Russell 3000 Index and the small-cap focused Russell 2000 Index, as part of the Russell Indexes reconstitution for 2026. The June index reconstitution incorporates about 4,000 of the largest U.S. companies, based on their market capitalization as of the April 30 close.

M. A. Arkhipov/Shutterstock.com

Inclusion in the Russell 3000 Index results in automatic addition to either the Russell 1000 Index or the Russell 2000 Index. It also leads to inclusions across indexes that cover value or growth tilts.

CEO David Happel said this development speaks volumes about what Sagimet has achieved over the years, with people now expecting the company to start its Phase 3 clinical study on denifanstat. He further stated:

“If approved, denifanstat would be the first innovative oral treatment for acne vulgaris in patients aged 12 years and older in more than forty years. With the capital in place to fund our programs through 2028, including data readout of our planned denifanstat Phase 3 clinical trial in acne, we look forward to the broader visibility that inclusion in the Russell indexes brings.”

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a biopharmaceutical firm at the clinical stage making drug innovations based on fatty acid synthase. The company’s leading drug candidate is Denifanstat, which is an oral pill taken once a day to counter diseases associated with the malfunctioning of metabolic processes.

While we acknowledge the risk and potential of SGMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SGMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.

Hedge Fund Investor Letters and Updates for 2026 Q2

​Recently, on July 6, HSBC doubled the price target on Intel Corporation (NASDAQ:INTC) from $100 to $200, while maintaining a Buy rating on the shares. After the increase, HSBC has the highest price target on the Street for INTC. The firm noted that the upgrade reflects a stronger server CPU outlook and also a valuation that includes the company’s foundry business.

​HSBC sees CPU growth as a key driver for earnings in 2026-27. The firm raised the 2026 shipment growth estimate to 25% from 20% and the 2027 estimate from 20% to 30%. Moreover, the firm’s data center and AI revenue forecasts of $24.1 billion for 2026 and $33.0 billion for 2027 sit well above consensus.

​In terms of foundry, HSBC called Intel’s foundry business too good to ignore. The firm believes that it positions the company as a credible TSMC alternative given fabrication and packaging constraints elsewhere. HSBC highlighted that Intel has already signed Terafab and Apple as customers and is in talks with Google and Nvidia.

Intel Corporation (NASDAQ:INTC) is a semiconductor company specializing in computing & related end products and services through its CCG, DCAI, and Intel Foundry segments.

While we acknowledge the risk and potential of INTC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INTC and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

​Recently, on July 5, Goldman Sachs analyst James Schneider raised the firm’s price target on Sandisk Corporation (NASDAQ:SNDK) from $1,200 to $2,200 and reiterated a Buy rating on the shares. The analyst is bullish on the stock ahead of the earnings as he expects a very strong quarter driven by continued NAND supply tightness.

​Schneider noted that management has given very positive commentary over the past few weeks and has given encouraging signals from customer agreements disclosed after peer Micron’s earnings. The analyst has raised his estimates on improving NAND pricing trends. He expects meaningful upside to both results and guidance, with higher contract pricing assumptions partly offset by increased operating expenses. His CY26 non-GAAP EPS estimate now sits roughly 30% above Street consensus. Schneider expects investors to focus heavily on long-term agreements. Moreover, NAND pricing is also expected to stay in focus, with attention on supply-demand dynamics, potential new supply, and pricing trends through 2026.

​Post-earnings, he expects continued investor focus on the depth of industry undersupply, whether NAND price increases hold up over coming quarters, and further LTA details.

Sandisk Corporation (NASDAQ:SNDK) develops and manufactures data storage devices and solutions based on NAND flash technology. Its offerings include solid-state drives, embedded products, removable cards, USB drives, and wafers and components, sold through consumer brands and global franchises.

While we acknowledge the risk and potential of SNDK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SNDK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

​Recently, on July 9, TD Cowen analyst Krish Sankar raised the firm’s price target on the stock from $340 to $400 and maintained a Buy rating on the shares. The firm noted updating its model for the company ahead of the earnings season.

​On the same day, Mizuho also raised the price target on LRCX from $380 to $400 and maintained an Outperform rating on the shares. Mizuho noted that they expect the wafer fab equipment to rise from 2027-29, driven by durable AI-driven demand. Moreover, the firm also expects ramp-ups across leading-edge logic and memory chips to continue over the said period.

​Mizuho noted it is raising price targets across the semiconductor equipment space more broadly, as AI continues to drive demand for leading-edge foundry and logic capacity as well as DRAM.

Lam Research Corporation (NASDAQ:LRCX) supplies semiconductor manufacturing equipment and services globally.

While we acknowledge the risk and potential of LRCX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LRCX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

​On July 9, Reuters reported that European stocks rose on Thursday after a three-day losing streak. The gains were driven by a greater tech sector rebound as tensions in the Middle East eased. Reuters noted that the STOXX 600 climbed about 0.8% to 640.88 points.

​Notably, ASML Holding N.V. (NASDAQ:ASML) was among the chip stocks driving the rally, gaining 4.8%. It was part of a broader surge in semiconductor names, with peers Siltronic and Soitec jumping 13.4% and 5.9% respectively. According to Reuters, this was fueled by a report suggesting China could grant domestic AI firms limited access to Nvidia’s H200 chips, a development seen as a potential boost to AI infrastructure demand and a key driver for equipment makers like ASML.

​In addition, on July 7, Morgan Stanley raised the firm’s price target on ASML Holding N.V. (NASDAQ:ASML) from EUR 1,600 to EUR 1,830 and maintained a Buy rating on the shares. A day earlier, Bernstein had also raised the price target from $1,971 to $2,623, while maintaining a Buy rating on the shares.

ASML Holding (NASDAQ:ASML) is the world’s leading manufacturer of photolithography machines, which are critical, high-tech systems used by semiconductor companies (like TSMC, Intel, and Samsung) to print tiny circuit patterns onto silicon wafers, effectively creating microchips.

While we acknowledge the risk and potential of ASML as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ASML and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.

​The firm noted AMD to be among the major beneficiaries of the AI infrastructure boom as it sees more advanced models and growing inference and agentic use cases. Blair expects the company’s sales to grow from $52 billion in 2026 to over $104 billion in 2028 and non-GAAP EPS to reach $20 by 2028.

​Despite this optimistic outlook, the firm called the company’s GPU business an uphill battle against Nvidia. The firm noted that while AMD is accelerating its product roadmap, competition from other hyperscalers is limiting meaningful gains for the shares.

​The firm noted that at 33 times  2027 earnings, the valuation of AMD properly balances strong AI demand against competitive and spending risks.

Advanced Micro Devices Inc. (NASDAQ:AMD) is a leading semiconductor company specializing in high-performance computing and graphics solutions. Its broad product portfolio includes microprocessors, graphics processors, and system-on-chip (SoC) solutions designed for data centers, gaming, and embedded systems.

While we acknowledge the risk and potential of AMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than AMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT:  10 Good Stocks to Invest in Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.